Trial Profile

A Phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts With KRAS G12C+ NSCLC and bRain Metastases

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Opnurasib (Primary)
Indications Brain metastases; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms STRIDER

Most Recent Events

28 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
12 Mar 2024 Planned initiation date changed from 1 Nov 2023 to 15 Apr 2024.
23 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com